Hints and tips:
Related Special Reports
...company’s biggest-selling drugs....
...AstraZeneca beat analysts’ estimates with 19 per cent growth in revenue in the first quarter of 2024, driven by stronger sales of its cancer drugs....
...The US biotech company reported first-quarter earnings of $3.67 a share, beating analysts’ consensus estimates of $3.44. That pushed Biogen’s shares up 4.3 per cent in early trading on Wednesday....
...Companies linked to the drug lost a combined $40bn in value in days. Pharma groups contest the lab’s results and practices....
...A Humira biosimilar from Teva Pharmaceuticals working with Alvotech earlier this year became the first drug that the US Food and Drug Administration granted interchangeable status, which lets pharmacists...
...“The biggest barrier is insurance companies,” said Lawrence Honig, a neurologist at New York’s Columbia University Irving Medical Center....
...The company said the decision was partly driven by huge demand for weight-loss drugs....
...The company’s work to date has involved analysing thousands of donated human livers to develop an understanding of the causes of disease, and studying whether making changes to RNA — a vital molecule for...
...The company has genetically validated two other drug targets....
...Patients with terminal breast cancer in England will be denied access to a new treatment that has already been approved in Scotland, after a public health body said the drug did not provide value for money...
...A top EU court has ruled that the name of the dead Colombian drug kingpin Pablo Escobar cannot be registered as a trademark in the EU....
...Patients with terminal breast cancer in England will miss out on a new drug already approved in Scotland, after spending watchdog NICE said Enhertu, developed by Japanese pharma company Daiichi Sankyo and...
...The ruling came after Escobar Inc, the company set up by his brother, filed an application in 2021 with the European Union Intellectual Property Office (EUIPO) for registration of the word sign Pablo Escobar...
...It is now raising $600mn to launch its pioneering drug Rezdiffra in the US. Madrigal’s market value is about $5.1bn....
...Emblaveo, marketed in Europe by US pharmaceutical company Pfizer, combines two existing medicines to tackle so-called Gram-negative bacteria that are among the leading drug-resistance threats....
...Hong Kong-based activist fund Oasis Management has bought a 9.6 per cent stake in the company, which has a market value of $1.2bn....
...The company’s immunotherapy drug Imfinzi helped patients with so-called limited stage small cell lung cancer survive for longer....
...Scientists have invented a potential drug candidate that successfully combats antibiotic-resistant “superbugs” in non-human tests, according to research....
...Finding an effective treatment for Alzheimer’s has proved fiendishly difficult for drug companies, and previous regulatory decisions in the field have stirred controversy....
...Soaring sales of the products have pushed the companies’ valuations to record highs....
...The company plans to “move forward as quickly as possible” with further trials in MASH for the drug....
...In its 2023 financial report, the company said the value of its primate assets had fallen by about $40mn....
...The deal between Amazon Pharmacy and Eli Lilly, the world’s largest drugmaker by market value, will allow Amazon to dispense medicines including the pharma group’s popular weight-loss injection pen....
...But healthcare providers must also decide whether weight-loss drugs represent value for money....
...The latest estimate of the value of its music rights has given the company an NAV per share of 92p....
International Edition